Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Cardiology/Vascular Diseases | Hematology | Family Medicine
Search Medical Condition
Dyslipidemia Clinical Trials
A listing of Dyslipidemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (73) clinical trials
Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of A Study Compound, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
A clinical research trial to prevent cardiovascular events due to high lipid or cholesterol levels
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia Protocol Number (AMG 145/Evolocumab) 20130287
Receive Evolocumab or Placebo for the treatment of Diabetics with High Cholesterol.
A Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk Not Adequately Controlled with Maximally Tolerated Statin Therapy
You are being asked to participate in a study of a new drug, Alirocumab [“study drug”] because you have high cholesterol despite the cholesterol lowering drugs you are currently taking. The study drug is a fully human monoclonal antibody (a type of protein). The study drug is a type of ...
FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease.
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD. The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.
A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes
Type 2 diabetes (T2D) is an increasing global problem, especially in developing countries. T2D is associated with an increased risk of cardiovascular disease (CVD), where hyperglycemia is especially important for microvascular damage. Previous studies in T2D on reduced carbohydrate intake has shown beneficial effects on glycemic control, indicated by reduction ...
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
The RCT will be conducted to test the screening intervention, the Cardiovascular Assessment Screening Program, with nurse practitioners across NL. Research Questions What is the effect of implementing the Cardiovascular Assessment Screening Program on comprehensiveness of screening by nurse practitioners in NL? What is the effect of implementation of the ...
Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease
Prevalence of type 2 diabetes in Asia seems to be almost epidemic and establishment of preventive strategy against macrovascular as well as microvascular diseases are warranted because of higher cardiovascular risk in diabetic patients even without history of atherosclerotic cardiovascular diseases. Benefit of lowering low density lipoprotein (LDL) cholesterol down ...
The Hellenic Postprandial Lipemia Study (HPLS)
The study aims to recruit 1200 patients that are characterized either as high risk or very-high risk for Coronary Heart Disease. It is assumed that an equal number of high risk and very high risk patients will be included in the study. Patients will be invited to participate in the ...
Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years in Europe, and is also increasingly common in developing countries. In the European Union, the economic cost of CVD represents annually 192 billion in ...
